8432 results for "canc*"

in 14.45 milliseconds.

• WTS data from NeoPancOne trial

  WTS data for pancreatic cancer samples (NeoPancOne Trial; NeoPancOne Study, McLaughlin et al., 2026).  The dataset includes tumour bam files sequenced on Illumina NovaSeq and aligned against GRCh38 (n=51 tumours)

  Dataset EGAD50000002953

• Digital mRNA-seq FASTQ files from the PEGASUS colorectal cancer cohort

  This dataset contains raw single-end FASTQ files generated with the NEGEDIA Digital mRNA-seq clinical-grade sequencing service (Next Generation Diagnostic srl) on an Illumina NovaSeq 6000, from FFPE tumor tissue samples of the PEGASUS colorectal cancer cohort.

  Dataset EGAD50000002963

• BIONIKK_Translational Research_Data Access Committee

  BIONIKK is a Phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer. The BIONIKK Translational Research Data Access Committee (DAC) is responsible for overseeing access to controlled-access datasets generated within translational and ancillary research projects associated with the BIONIKK clinical study. The DAC operates under the responsibility of ARTIC, Sponsor of the BIONIKK clinical study and Data Controller for BIONIKK data. The DAC oversees several datasets generated by different translational or ancillary research partners within BIONIKK. Specific access conditions applicable to a particular research project, partner or dataset shall be defined in the corresponding Data Access Policy.

  Dac EGAC50000001158

• UNICORN trial ST

  The UNICORN study aims to characterize the spatial organization and transcriptional states of the colorectal cancer microenvironment and to investigate how these features change in the context of therapy. This dataset contains raw paired-end sequencing data generated using the 10x Genomics Visium HD spatial transcriptomics platform from 56 colorectal cancer tissue samples, including matched pre-treatment and post-treatment specimens where available. The data are intended to support spatially resolved analyses of tumor–microenvironment interactions, cellular composition, molecular heterogeneity and treatment-associated remodeling.

  Study EGAS50000002020

• Whole genome sequencing data of high-grade serous ovarian cancer samples (set 18)

  The dataset contains whole genome sequencing data of 34 high-grade serous carcinoma (HGSC) patients sequenced with Novoseq 6000. The 98 samples are either fresh frozen tumour samples or blood samples. The files provided are paired fastq files.

  Dataset EGAD50000002796

• Spatial transcriptomic profiling of IOKIN samples

  This study aimed t o define the spatial tumor microenvironment features associated with response to immune checkpoint blockade in recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC). Spatial transcriptomic profiling was performed on tumor biopsies from ICB-naive patients to characterize malignant, stromal, and immune cell states and their spatial interactions. The study investigated how intratumoral heterogeneity, cancer-associated fibroblast programs, immune contexture, and tumor-microenvironment signaling relate to subsequent clinical response and progression-free survival following immunotherapy.

  Dataset EGAD50000003147

• TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

  We examined tumours from a large cohort of patients with metastatic urothelial bladder cancer (mUC) treated with an anti–PD-L1 agent (atezolizumab) and identified major determinants of clinical response and immune escape. Whole transcriptome profiles were generated for 368 patients using TruSeq RNA Access technology (Illumina). Somatic mutations were determined via whole exome sequencing for a subset of these patients. - Response was associated with CD8+ T effector cell phenotype and, to an even greater extent, high neoantigen or tumour mutation burden (TMB). On the other hand, lack of response was associated with a transforming growth factor β (TGF-β) signature, particularly in patients with CD8+ T cells preferentially residing in collagen-rich matrix surrounding tumours. Integration of these three independent biological features provided the best basis for understanding outcome in this setting. -

  Study EGAS00001002556

• Psoriatic_arthritis

  This is a pilot single cell mRNA sequencing experiment to study immune cells in psoriatic arthritis.

  Study EGAS00001002104

• IMMUcan BC1 cohort

  The goal of IMMUcan is to understand how the immune system interacts with tumors and how therapeutic interventions influence this interaction. This cohort includes metastatic Triple Negative Breast Cancer (mTNBC) patients, naïve of treatment in the metastatic settings, treated in 1st line with chemotherapy or chemo-immunotherapy Comprehensive profiling data are integrated with longitudinally collected clinical information. Cellular profiling of the same tumor samples was performed using multiplex immunofluorescence imaging, imaging mass cytometry, and H&E staining.

  Study EGAS50000001587

• PEGASUS cohort transcriptomic profiling

  This study characterizes the transcriptomic landscape of FFPE tumor tissue samples from the PEGASUS colorectal cancer cohort using Digital mRNA-seq (NEGEDIA, Next Generation Diagnostic srl). Libraries were sequenced single-end on an Illumina NovaSeq 6000.

  Study EGAS50000002062